Optimal treatment of actinic keratosis

Gary GoldenbergMount Sinai School of Medicine, New York, NY, USAWe read with interest the review by Uhlenhake on treatments for actinic keratosis (AK).1 The author presents a summary of the various AK treatment options used to reduce the risk of progression to invasive squamous cell carcinoma. The a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Goldenberg G
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	actinic keratosis Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/536715e5f0dd4060960bd958dcc52923
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:536715e5f0dd4060960bd958dcc52923
record_format	dspace
spelling	oai:doaj.org-article:536715e5f0dd4060960bd958dcc529232021-12-02T00:56:19ZOptimal treatment of actinic keratosis1178-1998https://doaj.org/article/536715e5f0dd4060960bd958dcc529232013-12-01T00:00:00Zhttps://www.dovepress.com/letter-optimal-treatment-of-actinic-keratoses-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Gary GoldenbergMount Sinai School of Medicine, New York, NY, USAWe read with interest the review by Uhlenhake on treatments for actinic keratosis (AK).1 The author presents a summary of the various AK treatment options used to reduce the risk of progression to invasive squamous cell carcinoma. The article includes a table (Table 1) comparing advantages and side effects of these options.Patient-administered topical treatments are an important strategy for treating confluent AKs and areas of sun-damaged skin that may contain subclinical AKs. Rates of complete and partial clearance are similar across the topical agents (fluorouracil, imiquimod, diclofenac, and ingenol mebutate). It is noteworthy that the uniquely brief regimen for ingenol mebutate, 2 to 3 days, produced clearance rates similar to those with the other agents, which have treatment regimens of several weeks.1View original paper by Uhlenhake.Goldenberg GDove Medical Pressarticleactinic keratosisGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 9, Pp 15-16 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	actinic keratosis Geriatrics RC952-954.6
spellingShingle	actinic keratosis Geriatrics RC952-954.6 Goldenberg G Optimal treatment of actinic keratosis
description	Gary GoldenbergMount Sinai School of Medicine, New York, NY, USAWe read with interest the review by Uhlenhake on treatments for actinic keratosis (AK).1 The author presents a summary of the various AK treatment options used to reduce the risk of progression to invasive squamous cell carcinoma. The article includes a table (Table 1) comparing advantages and side effects of these options.Patient-administered topical treatments are an important strategy for treating confluent AKs and areas of sun-damaged skin that may contain subclinical AKs. Rates of complete and partial clearance are similar across the topical agents (fluorouracil, imiquimod, diclofenac, and ingenol mebutate). It is noteworthy that the uniquely brief regimen for ingenol mebutate, 2 to 3 days, produced clearance rates similar to those with the other agents, which have treatment regimens of several weeks.1View original paper by Uhlenhake.
format	article
author	Goldenberg G
author_facet	Goldenberg G
author_sort	Goldenberg G
title	Optimal treatment of actinic keratosis
title_short	Optimal treatment of actinic keratosis
title_full	Optimal treatment of actinic keratosis
title_fullStr	Optimal treatment of actinic keratosis
title_full_unstemmed	Optimal treatment of actinic keratosis
title_sort	optimal treatment of actinic keratosis
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/536715e5f0dd4060960bd958dcc52923
work_keys_str_mv	AT goldenbergg optimaltreatmentofactinickeratosis
_version_	1718403382457139200

Optimal treatment of actinic keratosis

Ejemplares similares